Delfini Lisa 4
4 · Trevi Therapeutics, Inc. · Filed Sep 13, 2023
Insider Transaction Report
Form 4
Delfini Lisa
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2023-09-11$0.51/sh+2,291$1,171→ 35,105 total - Exercise/Conversion
Stock Option (right to buy)
2023-09-11−2,291→ 66,460 totalExercise: $0.51Exp: 2032-02-10→ Common Stock (2,291 underlying) - Sale
Common Stock
2023-09-11$2.20/sh−711$1,564→ 34,394 total
Footnotes (3)
- [F1]This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 13, 2022.
- [F2]This sale represents the sale of shares necessary to meet tax withholding obligations as a result of the exercise of stock options on September 11, 2023.
- [F3]This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.